{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:38:58Z","timestamp":1793648338895,"version":"4.5.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine\/tipiracil (FTD\/TPI), we identified <jats:italic>KRAS<\/jats:italic> codon G12 (<jats:italic>KRAS<\/jats:italic><jats:sup>G12<\/jats:sup>) mutations as a potential biomarker of resistance. Next, we collected real-world data of 960 patients with mCRC receiving FTD\/TPI and validated that <jats:italic>KRAS<\/jats:italic><jats:sup>G12<\/jats:sup> mutations were significantly associated with poor survival, also in analyses restricted to the <jats:italic>RAS<\/jats:italic>\/<jats:italic>RAF<\/jats:italic> mutant subgroup. We next analyzed the data of the global, double-blind, placebo-controlled, phase 3 RECOURSE trial (<jats:italic>n<\/jats:italic>\u2009=\u2009800 patients) and found that <jats:italic>KRAS<\/jats:italic><jats:sup>G12<\/jats:sup> mutations (<jats:italic>n<\/jats:italic>\u2009=\u2009279) were predictive biomarkers for reduced overall survival (OS) benefit of FTD\/TPI versus placebo (unadjusted interaction <jats:italic>P<\/jats:italic>\u2009=\u20090.0031, adjusted interaction <jats:italic>P<\/jats:italic>\u2009=\u20090.015). For patients with <jats:italic>KRAS<\/jats:italic><jats:sup>G12<\/jats:sup> mutations in the RECOURSE trial, OS was not prolonged with FTD\/TPI versus placebo (<jats:italic>n<\/jats:italic>\u2009=\u2009279; hazard ratio (HR)\u2009=\u20090.97; 95% confidence interval (CI)\u2009=\u20090.73\u20131.20; <jats:italic>P<\/jats:italic>\u2009=\u20090.85). In contrast, patients with <jats:italic>KRAS<\/jats:italic><jats:sup>G13<\/jats:sup> mutant tumors showed significantly improved OS with FTD\/TPI versus placebo (<jats:italic>n<\/jats:italic>\u2009=\u200960; HR\u2009=\u20090.29; 95% CI\u2009=\u20090.15\u20130.55; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In isogenic cell lines and patient-derived organoids, <jats:italic>KRAS<\/jats:italic><jats:sup>G12<\/jats:sup> mutations were associated with increased resistance to FTD-based genotoxicity. In conclusion, these data show that <jats:italic>KRAS<\/jats:italic><jats:sup>G12<\/jats:sup> mutations are biomarkers for reduced OS benefit of FTD\/TPI treatment, with potential implications for approximately 28% of patients with mCRC under consideration for treatment with FTD\/TPI. Furthermore, our data suggest that genomics-based precision medicine may be possible for a subset of chemotherapies.<\/jats:p>","DOI":"10.1038\/s41591-023-02240-8","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T17:03:13Z","timestamp":1677776593000},"page":"605-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer"],"prefix":"10.1038","volume":"29","author":[{"given":"Joris","family":"van de Haar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-3376","authenticated-orcid":false,"given":"Salo N.","family":"Ooft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim W.","family":"van der Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa R.","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mainardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-4962","authenticated-orcid":false,"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina Valeria","family":"Zurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Giampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7979-4795","authenticated-orcid":false,"given":"Fabio","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mazzuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chara","family":"Stavraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Rodriquenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pavarana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Iveson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zoratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-0955","authenticated-orcid":false,"given":"Elisabetta","family":"Fenocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Depetris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Cergnul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Libertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Zanaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Longarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Maria","family":"Gobba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicla","family":"La Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1656-6995","authenticated-orcid":false,"given":"Lodewyk F. A.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":false,"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-9586","authenticated-orcid":false,"given":"Emile E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5426-5683","authenticated-orcid":false,"given":"Nicola","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"2240_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386\u20131422 (2016).","journal-title":"Ann. Oncol."},{"key":"2240_CR2","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/1078-0432.CCR-16-2157","volume":"23","author":"L Marcus","year":"2017","unstructured":"Marcus, L. et al. FDA approval summary: TAS-102. Clin. Cancer Res. 23, 2924\u20132927 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2240_CR3","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2240_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2017.10.009","volume":"90","author":"E Van Cutsem","year":"2018","unstructured":"Van Cutsem, E. et al. The subgroups of the phase III RECOURSE trial of trifluridine\/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur. J. Cancer 90, 63\u201372 (2018).","journal-title":"Eur. J. Cancer"},{"key":"2240_CR5","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2240_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2240_CR7","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook, A. P. et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317, 2392\u20132401 (2017).","journal-title":"JAMA"},{"key":"2240_CR8","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306\u20131315 (2015).","journal-title":"Lancet Oncol."},{"key":"2240_CR9","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker, D. J. et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040\u20132048 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2240_CR10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091\u20132096 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2240_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/JCO.2015.63.9674","volume":"34","author":"CJ Allegra","year":"2016","unstructured":"Allegra, C. J. et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J. Clin. Oncol. 34, 179\u2013185 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2240_CR12","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757\u20131765 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2240_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"2240_CR14","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1021\/acs.chemrev.5b00542","volume":"116","author":"S Lu","year":"2016","unstructured":"Lu, S. et al. Ras conformational ensembles, allostery, and signaling. Chem. Rev. 116, 6607\u20136665 (2016).","journal-title":"Chem. Rev."},{"key":"2240_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JM Ostrem","year":"2016","unstructured":"Ostrem, J. M. & Shokat, K. M. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug Discov. 15, 771\u2013785 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2240_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","volume":"18","author":"S Li","year":"2018","unstructured":"Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767\u2013777 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2240_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216 (2019).","journal-title":"Nature"},{"key":"2240_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","volume":"32","author":"LM Ellis","year":"2014","unstructured":"Ellis, L. M. et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 32, 1277\u20131280 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2240_CR19","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper, L. E. et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J. Clin. Oncol. 33, 2563\u20132577 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2240_CR20","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1093\/annonc\/mdw258","volume":"28","author":"NI Cherny","year":"2017","unstructured":"Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 28, 2901\u20132905 (2017).","journal-title":"Ann. Oncol."},{"key":"2240_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","volume":"7","author":"KR Johnson","year":"2006","unstructured":"Johnson, K. R. et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 7, 741\u2013746 (2006).","journal-title":"Lancet Oncol."},{"key":"2240_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532\u2013536 (2012).","journal-title":"Nature"},{"key":"2240_CR23","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.3390\/jcm10235568","volume":"10","author":"IA Voutsadakis","year":"2021","unstructured":"Voutsadakis, I. A. Biomarkers of trifluridine-tipiracil efficacy. J. Clin. Med. 10, 5568 (2021).","journal-title":"J. Clin. Med."},{"key":"2240_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.clcc.2021.09.009","volume":"20","author":"C Stavraka","year":"2021","unstructured":"Stavraka, C. et al. Trifluridine\/tipiracil in metastatic colorectal cancer: a UK multicenter real-world analysis on efficacy, safety, predictive and prognostic factors. Clin. Colorectal Cancer 20, 342\u2013349 (2021).","journal-title":"Clin. Colorectal Cancer"},{"key":"2240_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch, P. M. & Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515\u2013526 (1994).","journal-title":"Biometrika"},{"key":"2240_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymeth.2017.03.021","volume":"121\u2013122","author":"AM Jacobi","year":"2017","unstructured":"Jacobi, A. M. et al. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes. Methods 121\u2013122, 16\u201328 (2017).","journal-title":"Methods"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02240-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02240-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02240-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T14:17:32Z","timestamp":1679494652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02240-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02240-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.E.V. reports research grants from Roche, Pfizer, GSK, Novartis, Merck, Bristol Myers Squibb, AstraZeneca, Amgen, Bayer, Sanofi, Seagen, Janssen, Eisai, Ipsen and Lilly. He is a founder, strategic advisor and shareholder of MOSAIC Therapeutics and nonexecutive, independent director and shareholder of Sanofi, all outside the submitted work. L.F.A.W. reports grants from Genmab, outside the submitted work. A.C. received grant consultancy fees from MSD, AstraZeneca, Oncoc4 and IQVIA. He also declares speaker\u2019s fees from Eisai and AstraZeneca. A.P. received personal fees from Lilly, Servier, Merck, Amgen, Bristol Myers Squibb and MSD. A.T. declares speaker bureau fees from Bristol Myers Squibb and Servier. C.S. received honoraria from the speaker bureau at Servier. D.J.P. received lecture fees from ViiV Healthcare, Bayer Healthcare, Bristol Myers Squibb, Roche, Eisai and the Falk Foundation, travel expenses from Bristol Myers Squibb and Bayer Healthcare, consulting fees for Mina Therapeutics, H3B, Eisai, Roche, DaVolterra, Mursla, Exact Sciences, Avamune and AstraZeneca and research funding (to institution) from MSD, Bristol Myers Squibb and GSK. F.G. received honoraria for speaker\/advisory roles from Servier, Lilly, IQVIA, Merck Serono, Bayer, Amgen and Bristol Myers Squibb outside the present work. F.M. received fees from the speaker bureaux of Servier, Amgen, Novartis, MSD and Merck. G.T. took part in the advisory boards for Bristol Myers Squibb, AstraZeneca, MSD, Merck and Servier. J.G. received honoraria for educational events organized by Servier. L.S. received speaker and consultancy fees from MSD, AstraZeneca, Servier, Bayer, Merck, Amgen and Pierre-Fabre. M.G.R. received consultancy fees from Roche. M.G. received grants and advisory board fees from Merck, Servier, Lilly, Amgen and Italfarmaco. N.L.V. received fees and honoraria from Eisai, MSD, Roche, Novartis, AstraZeneca, GSK, Pfizer, Gentili and Lilly. N.V. received honoraria from Merck Serono, Pfizer, Bayer, Lilly and Servier, consultancy fees from BenevolentAI and grants (institutional) from Roche and BenevolentAI. N.Z. declares personal fees from Bayer and Eisai. O.G. reports consulting fees from Eisai, Lilly, MSD and Seagen and payment or honoraria for lectures, presentations, speaker bureaux fees, manuscript writing or educational events from Novartis, Lilly and Eisai. P.R. received grants from Bayer and Sanofi, honoraria for advisory boards from AstraZeneca, Eisai, Servier and Sirtex, speaking fees from Amgen, Boston Scientific, HMP Education, Eisai, Roche and Servier and travel conference support from Bayer, Roche, Ipsen and Servier. R.G. took part in advisory boards for Merck, Amgen, Servier and Bayer. R.B. declares consultancies, advisory board roles and\/or institutional donations from AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Lully, Roche, Amgen, GSK and Eisai. T.I. received honoraria for educational symposia run by Servier. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}